Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regeneron (REGN – Research Report) and Avrobio (AVRO – Research Report). Regeneron (REGN) Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Regeneron today and set a price target of $571.00. The company's shares closed last Tuesday at $547.17. According to TipRanks.com, Harrison is a 5-star analyst with an average return of 15.1% and a 57.1% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Global Blood Therapeutics. Currently, the analyst consensus on Regeneron is a Moderate Buy with an average price target of $708.08. See today’s best-performing stocks on TipRanks >> Avrobio (AVRO) In a report released today, David Lebovitz from Morgan Stanley maintained a Buy rating on Avrobio, with a price target of $25.00. The company's shares closed last Tuesday at $5.54, close to its 52-week low of $5.23. According to TipRanks.com, Lebovitz is a 3-star analyst with an average return of 3.2% and a 57.8% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Karyopharm Therapeutics, and Rhythm Pharmaceuticals. Currently, the analyst consensus on Avrobio is a Strong Buy with an average price target of $22.25. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on REGN: William Blair Maintains Their Buy Rating on DocuSign (DOCU) Russel Metals (RUSMF) Receives a Buy from BMO Capital William Blair Thinks Poseida Therapeutics’ Stock is Going to Recover Advantage Energy (AAVVF) Gets a Buy Rating from CIBC Union Pacific: Valuation Looks Attractive